Clin Lipidology. 2013;8(3):345-359.

Cover picture: Inspired by the Review by Jung-Soon Mo, Hyun Woo Park and Kun-Liang Guan. Illustrated by Sandra Krahl.

which has lead candidate BMS-986020 – a lysophosphatidic acid (LPA1) receptor antagonist – in phase II testing for IPF. In November 2014, BMS reached an agreement to acquire Galecto Biotech in ...

After hours: January 2 at 4:20:01 PM EST Loading Chart for CTNM ...

Introduction: Breast cancer is the most common form of cancer diagnosed worldwide and the leading cause of death in women globally, according to Globocan 2020. Hence, investigating novel pathways ...

into a signalling molecule known as lysophosphatidic acid (LPA). These signals can induce various responses along multiple cellular signalling pathways that lead to a build up of fibroblasts.

This month's cover highlights the article An octameric PqiC toroid stabilises the outer-membrane interaction of the PqiABC transport system by Benjamin Cooper, Timothy Knowles, and colleagues. The ...

From the Centers of Inflammation, Translational, and Clinical Lung Research (Y. Shao, Y. Sun, Y.L., F.S., C.D., C.J., K.X., X.J., X.Y.), Temple University, Lewis Katz ...

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive ...

After hours: January 3 at 7:53:21 p.m. EST ...